Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2025-02-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于第八届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Anhui Anke Biotechnology (Group) Co., Ltd. It details the approval of an investment proposal by the company's board of directors. The text includes voting results and authorizations related to the investment. There is no financial report, earnings data, or detailed financial statements. The document is a formal announcement of a board decision, not a full management report or financial filing. Therefore, it fits best under 'Board/Management Information' (MANG). The document length is short and focused on board resolutions, not a report publication or regulatory filing. Confidence is high due to clear keywords like '董事会会议决议' (board meeting resolution) and voting results.
2025-02-11 Chinese
关于公司作为基石投资者参与维昇药业香港首次公开发行的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Anhui Anke Biotechnology (Group) Co., Ltd. regarding its participation as a cornerstone investor in the initial public offering (IPO) of VISEN Pharmaceuticals on the Hong Kong Stock Exchange. It details the investment overview, the target company's background, financial data, investment agreement terms, risks, and impact on the company. The document is relatively short (4200 characters) and focuses on the company's financing activity related to a capital investment in another company. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or voting announcement. The content fits best under Capital/Financing Update (CAP) as it provides an update on the company's financing activity and capital investment.
2025-02-11 Chinese
关于全资子公司头孢克洛分散片通过仿制药质量和疗效一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Bioengineering (Group) Co., Ltd. regarding its wholly-owned subsidiary's product (Cefaclor Dispersible Tablets) passing the generic drug quality and efficacy consistency evaluation by the National Medical Products Administration. The text includes regulatory references, product details, and a risk warning to investors. It is a regulatory announcement about a product approval and evaluation result, not a financial report, management change, or shareholder meeting material. The document length is short (1021 characters) and it is an announcement of a regulatory approval event. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like financial reports or management changes.
2025-02-11 Chinese
关于人生长激素注射液新增适应症获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology (Group) Co., Ltd. regarding the approval of a supplemental drug application for a new indication of their human growth hormone injection. It includes details about the approval notice from the National Medical Products Administration, the clinical trial application approval, and risk warnings related to the drug development process. There is no financial data, no mention of annual or quarterly reports, no discussion of management changes, no voting results, and no earnings information. The document is a regulatory announcement about a drug approval and clinical trial application, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Legal Proceedings. The document length is short and it is an announcement, not a full report or presentation.
2025-02-06 Chinese
关于参股公司药品临床试验申请获受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a clinical trial application for a drug by a regulatory body (National Medical Products Administration's Center for Drug Evaluation). It provides details about the drug, the application, and a risk warning. The document is short (969 characters) and is an announcement of a regulatory event related to the company's business activities, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a clinical trial application acceptance, which does not fit other more specific categories.
2025-01-24 Chinese
2024年前三季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of a profit distribution (dividend) plan for the first three quarters of 2024, approved at a recent shareholders' meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It does not contain financial statements or comprehensive financial performance data but focuses solely on the dividend distribution details. The document length is relatively short (2601 characters) and is clearly an announcement of dividend distribution rather than a full financial report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2025-01-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.